Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AXSM Axsome Therapeutics, Inc.

盘前交易 07-30 07:15:19 EDT

227.42

-6.78

-2.89%

最高235.91	最低227.00	成交量52.31万
今开233.96	昨收234.20	日振幅3.80%
总市值117.03亿	流通市值97.59亿	总股本5,146万
成交额1.20亿	换手率1.22%	流通股本4,291万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AXSM","market":"US","secType":"STK","nameCN":"Axsome Therapeutics, Inc.","latestPrice":227.42,"timestamp":1785355200000,"preClose":234.2,"halted":0,"volume":523066,"delay":0,"changeRate":-0.02894961571306576,"floatShares":42910423,"shares":51459766,"eps":-3.741443,"marketStatus":"盘前交易","change":-6.78,"latestTime":"07-30 07:15:19 EDT","open":233.96,"high":235.91,"low":227,"amount":119918461.61422001,"amplitude":0.038044,"askPrice":234.65,"askSize":50,"bidPrice":222.01,"bidSize":13,"shortable":3,"etf":0,"ttmEps":-3.741443,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785418200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1447909200000,"exchange":"NASDAQ","adjPreClose":227.42,"postHourTrading":{"tag":"盘后","latestPrice":226,"preClose":227.42,"latestTime":"19:41 EDT","volume":9046,"amount":2056280.65,"timestamp":1785368510818,"change":-1.42,"changeRate":-0.006244,"amplitude":0.019963},"volumeRatio":0.9381255998068163,"impliedVol":0.5026,"impliedVolPercentile":0.872},"requestUrl":"/m/hq/s/AXSM/wiki","defaultTab":"wiki","newsList":[{"id":"1116287182","title":"Axsome Therapeutics宣布FDA受理Axs-12治疗发作性睡病中猝倒症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1116287182","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116287182?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:02","pubTimestamp":1784113338,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics公司宣布，美国食品药品监督管理局（FDA）已正式受理其新药Axs-12用于治疗发作性睡病中猝倒症的新药申请。这一进展标志着该药物向上市迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AXSM","PTH","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105093932","title":"Axsome Therapeutics启动Solriamfetol治疗儿童注意缺陷多动障碍的Focus-2三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1105093932","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105093932?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:04","pubTimestamp":1783422284,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics已正式启动其候选药物Solriamfetol针对儿童注意缺陷多动障碍的Focus-2三期临床试验。这项研究旨在评估该药物在年轻患者群体中的安全性与有效性，标志着公司在该治疗领域研发进程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AXSM","BK4007","PTH","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132235371","title":"Axsome Therapeutics启动Solriamfetol治疗青少年注意力缺陷多动障碍的FOCUS-3三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1132235371","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132235371?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:00","pubTimestamp":1782471654,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics已正式启动其药物Solriamfetol用于治疗青少年注意力缺陷多动障碍的FOCUS-3三期临床研究。该试验旨在评估该疗法在青少年患者群体中的安全性与有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AXSM","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152330928","title":"异动解读 | 多家华尔街分析师上调目标价，Axsome Therapeutics盘中大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152330928","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152330928?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:34","pubTimestamp":1777901649,"startTime":"0","endTime":"0","summary":"生物制药公司Axsome Therapeutics今日盘中股价大幅上涨5.03%，引起了市场参与者的关注。消息面上，多家华尔街知名券商在今日发布的研究报告中，纷纷上调了该公司的目标股价。分析师们集体上调目标价的行动，通常被视为对公司未来业绩和增长前景的积极预期，这直接提振了市场信心，推动了股价在交易时段内的强劲表现。投资者对此作出反应，导致该股在开盘后不久即出现显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194346361","title":"Axsome Therapeutics宣布FDA批准Auvelity®用于治疗阿尔茨海默病相关痴呆激越症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1194346361","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194346361?lang=zh_cn&edition=full","pubTime":"2026-05-01 02:08","pubTimestamp":1777572495,"startTime":"0","endTime":"0","summary":"生物制药公司Axsome Therapeutics宣布，其创新药物Auvelity®（右美沙芬氢溴酸盐与安非他酮盐酸盐复方制剂）已获得美国食品药品监督管理局（FDA）批准，用于治疗由阿尔茨海默病引起的痴呆相关的激越症状。\n此次获批标志着Auvelity®在现有适应症基础上的重要拓展，为阿尔茨海默病相关激越症状的治疗提供了新的药物选择。激越症状是痴呆患者常见的神经精神症状，对患者及其照护者的生活质量构成显著挑战。\nAuvelity®作为一种新型口服疗法，其独特的双重作用机制旨在调节与情绪和行为相关的神经递质系统。该药物的批准基于其临床试验中展现出的有效性和安全性数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4007","BK4585","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186909738","title":"财报前瞻｜Axsome Therapeutics, Inc.本季度营收预计增59.11%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1186909738","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186909738?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:01","pubTimestamp":1777251719,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.将于2026年05月04日发布财报，市场聚焦营收高增与管线催化落地节奏。市场一致预期本季度营收为1.91亿美元，同比增59.11%；调整后每股收益为-0.87美元，同比改善34.74%；同时预计EBIT为-4,227.66万美元，同比改善31.23%；公司未提供本季度明确指引，毛利率与净利润或净利率的外部一致预期暂缺。公司目前主营以产品销售为核心，毛利率维持93.71%；发展前景最大的现有业务集中在产品销售板块，上季度产品收入为6.34亿美元，占比99.26%，带动公司季度总收入同比增长65.03%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Axsome Therapeutics, Inc.本季度营收预计增59.11%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145624149","title":"Axsome Therapeutics与武田制药达成协议：后者获首付款，并享有里程碑付款及特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1145624149","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145624149?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:02","pubTimestamp":1775041353,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics公司宣布，其合作伙伴武田制药已收到一笔首付款，并具备资格获得后续的里程碑付款及特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","AXSM","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124880040","title":"Axsome Therapeutics收购选择性Pde10a抑制剂Balipodect，用于治疗精神分裂症及其他神经精神疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1124880040","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124880040?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:01","pubTimestamp":1775041303,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics宣布收购选择性Pde10a抑制剂Balipodect，该药物将用于治疗精神分裂症及其他神经精神疾病。这一收购举措有望拓展公司在神经科学领域的治疗管线，为相关患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","AXSM","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116255362","title":"Axsome Therapeutics启动Solriamfetol针对伴有日间过度嗜睡症状的成人重度抑郁症患者的Clarity三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1116255362","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116255362?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:06","pubTimestamp":1771934761,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics已正式启动Clarity三期临床试验，该试验旨在评估Solriamfetol对伴有日间过度嗜睡症状的成人重度抑郁症患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AXSM","BK4007","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613973603","title":"Axsome Therapeutics, Inc.盘中异动 早盘股价大跌7.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613973603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613973603?lang=zh_cn&edition=full","pubTime":"2026-02-23 22:31","pubTimestamp":1771857106,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日22时31分，Axsome Therapeutics, Inc.股票出现波动，股价大幅下跌7.20%。截至发稿，该股报170.50美元/股，成交量5.9108万股，换手率0.12%，振幅4.22%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Arcellx, Inc.、Vanda Pharmaceuticals Inc.、Immunitybio, Inc.涨幅较大，Psyence Biomedical Ltd.、Cardio Diagnostics Holdings Inc.、Fortress Biotech, Inc.较为活跃，换手率分别为175.90%、32.84%、25.60%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc.、Camp4 Therapeutics Corporation、Aspire Biopharma Holdings, Inc.，振幅分别为11.46%、9.68%、9.50%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223146a4bf4c12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223146a4bf4c12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","AXSM","BK4139","BK4007","BK4539","LENZ","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148481433","title":"Axsome Therapeutics公布2025年第四季度及全年财报并发布业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1148481433","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148481433?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:03","pubTimestamp":1771848202,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics（纳斯达克代码：AXSM）今日正式披露2025财年第四季度及全年财务业绩报告，同时就公司最新业务动态进行说明。报告显示，该公司在神经系统疾病治疗领域的商业化产品组合持续放量，核心产品收入实现显著增长。管理层在财报中强调，公司现金流状况稳健，研发管线多项后期临床试验取得突破性进展，为2026年的业务扩张奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","AXSM","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119259700","title":"财报前瞻｜Axsome Therapeutics, Inc.营收预计增63.74%，机构偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1119259700","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119259700?lang=zh_cn&edition=full","pubTime":"2026-02-16 10:27","pubTimestamp":1771208878,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.将于2026年02月23日美股盘前发布最新财报，市场聚焦营收高增与盈利弹性的边际改善节奏。现有业务中展望最具发展弹性的板块为以Auvelity为代表的中枢神经系统用药商业化，本季度公司披露的约1.55亿美元净销售额为收入主引擎，并带动产品收入同比增长约63.22%，有望延续高增趋势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Axsome Therapeutics, Inc.营收预计增63.74%，机构偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518277592","title":"Axsome Therapeutics, Inc.盘中异动 急速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277592","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518277592?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:42","pubTimestamp":1741617767,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时42分，Axsome Therapeutics, Inc.股票出现异动，股价大幅跳水5.00%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3487.28%、761.92%、648.51%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.06%、41.36%、40.33%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224248abf31732&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224248abf31732&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4585","BK4505","AXSM","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516579633","title":"Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516579633","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516579633?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:51","pubTimestamp":1741006288,"startTime":"0","endTime":"0","summary":"Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03205148492765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514857535","title":"瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857535","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514857535?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:11","pubTimestamp":1740586273,"startTime":"0","endTime":"0","summary":"瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27001148413683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","161121","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132091385","title":"异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1132091385","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132091385?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:04","pubTimestamp":1740510275,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.(AXSM)今日盘中大跌5.03%,引发了市场广泛关注。\n\nAXSM是一家致力于开发治疗中枢神经系统疾病的新疗法的生物制药公司。从最新财报数据看,公司营收3.86亿美元,净利润则达-2.87亿美元,每股亏损5.99美元。较高的亏损可能是导致股价下跌的主要原因之一。\n\n同时,分析师普遍认为,该公司股价目前市盈率过高,约为-20.76倍,短期内增长动能不足,估值面临压力。机构方面给予100%买入评级,但显然并没能阻止股价下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514139048","title":"Axsome Therapeutics, Inc.盘中异动 下午盘快速下挫5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514139048","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514139048?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:01","pubTimestamp":1740510114,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时01分，Axsome Therapeutics, Inc.股票出现异动，股价快速下跌5.04%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1940.33%、1162.55%、995.72%，振幅较大的相关个股有Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp，振幅分别为241.19%、112.90%、87.83%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260301549892802b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260301549892802b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","AXSM","LENZ","BK4585","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778342","title":"Axsome Therapeutics, Inc.盘中异动 早盘股价大跌5.15%报130.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778342","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513778342?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:04","pubTimestamp":1740409483,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时04分，Axsome Therapeutics, Inc.股票出现异动，股价大幅下跌5.15%。截至发稿，该股报130.65美元/股，成交量22.0085万股，换手率0.45%，振幅4.89%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Pepgen Inc.、Telix Pharmaceutic、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为160.26%、70.68%、25.66%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、42.86%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230443abdb160d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230443abdb160d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4505","BK4139","AXSM","BK4585","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513902542","title":"Axsome Therapeutics, Inc.盘中异动 快速上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513902542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513902542?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:28","pubTimestamp":1740155326,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时28分，Axsome Therapeutics, Inc.股票出现异动，股价大幅拉升5.02%。截至发稿，该股报135.58美元/股，成交量43.6884万股，换手率0.90%，振幅5.52%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Nkgen Biotech, Inc.、Invivyd, Inc.、Osr Holdings, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为201.91%、142.45%、119.77%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为70.43%、57.50%、48.19%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002847abd7c910&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002847abd7c910&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4505","AXSM","BK4139","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513689292","title":"Axsome Therapeutics, Inc.2024财年实现净利润-2.87亿美元，同比减少20.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513689292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513689292?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:00","pubTimestamp":1740153636,"startTime":"0","endTime":"0","summary":"2月22日，Axsome Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.87亿美元，同比减少20.08%；其中营业收入为3.86亿美元，同比增加42.44%，每股基本收益为-5.99美元。机构评级：截至2025年2月22日，当前有17家机构对Axsome Therapeutics, Inc.目标价做出预测，其中目标均价为166.47美元，其中最低目标价为121.00美元，最高目标价为200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000053a24ec476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000053a24ec476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","AXSM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.axsome.com","stockEarnings":[{"period":"1week","weight":-0.0509},{"period":"1month","weight":-0.0568},{"period":"3month","weight":0.0947},{"period":"6month","weight":0.2343},{"period":"1year","weight":1.2649},{"period":"ytd","weight":0.2452}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.015},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.1483},{"period":"ytd","weight":0.0697}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Axsome Therapeutics, Inc.成立于2012年1月。该公司是一家临床阶段的生物制药企业，开发新的治疗疼痛和其他中枢神经系统或中枢神经系统，疾病管理。通过专注于这一治疗领域，他们正在解决显著和不断增长的市场，其中目前的治疗选择是有限或不充分的。他们的目标是成为一个完全集成的生物制药公司开发和商业化的拓展提供给医护人员的治疗方案，提高生活疼痛和其他中枢神经系统疾病患者的生命分化疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.074403},{"month":2,"riseRate":0.181818,"avgChangeRate":-0.03699},{"month":3,"riseRate":0.363636,"avgChangeRate":0.055503},{"month":4,"riseRate":0.727273,"avgChangeRate":0.158416},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.036488},{"month":6,"riseRate":0.636364,"avgChangeRate":0.116789},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.033776},{"month":8,"riseRate":0.6,"avgChangeRate":0.05275},{"month":9,"riseRate":0.5,"avgChangeRate":-0.019558},{"month":10,"riseRate":0.5,"avgChangeRate":0.012145},{"month":11,"riseRate":0.7,"avgChangeRate":0.154442},{"month":12,"riseRate":0.727273,"avgChangeRate":0.190318}],"exchange":"NASDAQ","name":"Axsome Therapeutics, Inc.","nameEN":"Axsome Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Axsome Therapeutics, Inc.(AXSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Axsome Therapeutics, Inc.,AXSM,Axsome Therapeutics, Inc.股票,Axsome Therapeutics, Inc.股票老虎,Axsome Therapeutics, Inc.股票老虎国际,Axsome Therapeutics, Inc.行情,Axsome Therapeutics, Inc.股票行情,Axsome Therapeutics, Inc.股价,Axsome Therapeutics, Inc.股市,Axsome Therapeutics, Inc.股票价格,Axsome Therapeutics, Inc.股票交易,Axsome Therapeutics, Inc.股票购买,Axsome Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Axsome Therapeutics, Inc.(AXSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}